4CPS-030 Patient-reported outcomes in interstitial lung disease and adherence to antifibrotic therapy

<h3>Background and Importance</h3> Interstitial lung disease (ILD) is a debilitating disease and there are limited therapies which focus on slowing disease progression. <h3>Aim and Objectives</h3> To describe Patient-Reported Outcomes (PROs) on ILD and analyse the relationship with disease perception, satisfaction with antifibrotic therapy and adherence. <h3>Material and Methods</h3> Retrospective, observational, descriptive study conducted by telephone surveys during February-March 2024 among patients with antifibrotic therapy. Surveys included: perception of disease, satisfaction with treatment (SATMED-Q survey) and Morisky-Green test (MG). <h3>Other variables collected were</h3> sex, age, education, type of ILD, duration of treatment and adherence (dispensing records in Farmatools (optimal &gt;80%)). <h3>Results</h3> 46 patients were included. 85% were male, median age 72 years. 13% had no education, 33% primary, 30% secondary and 24% university education. 41% were diagnosed with ILD with usual interstitial pneumonia pattern, 30% with idiopathic pulmonary fibrosis, 11% with ILD associated with autoimmune diseases and the rest with other ILDs. 85% were treated with nintedanib, 15% with pirfenidone. Median treatment duration: 13 months. Regarding perception of the disease 52% felt that ILD affected their daily life, 54% felt physically limited, 35% felt emotionally limited, 32% felt their social life was affected, 41% felt their sleep quality was affected and 48% of patients had stopped performing daily activities. 67% had an adverse event, mainly gastrointestinal. 20% of patients had their dose reduced. According to the SATMED-Q, the mean satisfaction with treatment was 74%. The MG test showed 30% non-adherence (NA), of which 85% was due to forgetting to take the medicine. According to dispensing records, 92% patients were adherent (A). Correlation with the MG test was low in NAs (only 14% detected) but high in As (91%). Of the 31 patients who had adverse events, 71% were adherent according to the MG test compared to 67% of the 15 patients who had no adverse effects. <h3>Conclusion and Relevance</h3> ILD is a disabling disease which make patients committed to their treatment despite the side effects. No relationship was found between education, adverse events or SATMED-Q score and adherence The most important factor associated with NA is forgetting to take medication; it would be important to use reminders in this population. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest